Why the study?
Hematological and neuromuscular genetic disorders benefit from genome editing but face distinct challenges in clinical translation.
Design
Review
Key result
CRISPR-based gene therapies demonstrate transformative potential for treating monogenic blood disorders and muscular dystrophy, though clinical translation faces challenges like in vivo delivery.
Authors
Loading...
Should not yet change clinical practice; leaves open optimization of in vivo delivery for broader translation.
This review summarizes the progress and challenges of CRISPR-based gene therapies for hematological and neuromuscular disorders, emphasizing recent clinical milestones and ongoing hurdles in delivery and safety.
Laurent et al. (2024) conducted a review in Inherited hematological and neuromuscular genetic disorders. CRISPR-based gene therapies was evaluated. CRISPR-based gene therapies demonstrate transformative potential for treating monogenic blood disorders and muscular dystrophy, though clinical translation faces challenges like in vivo delivery.